# Apitope: Research, Zomergem, Belgium

> Apitope: Apitope is a clinical-stage biotechnology company founded in 2002, based in Diepenbeek, Belgium, with a subsidiary in Bristol, UK.

Source: https://millionrounds.com/startup/apitope (Millionrounds; every figure on the page links to its filing or article)

Belgium · [Research startup](https://millionrounds.com/companies)

# Apitope

Apitope is a clinical-stage biotechnology company founded in 2002, based in Diepenbeek, Belgium, with a subsidiary in Bristol, UK.

Funding reported Last round: Series B

Research Zomergem, Belgium

Company summary

- **Founded:** 2002 24 years old
- **Team:** 1 1 to 10 people
- **Funding reported:** 22M as listed, currency not stated
- **Last round:** Series B Sept 2015

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Apitope has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Apitope

Apitope is a clinical-stage biotechnology company founded in 2002, based in Diepenbeek, Belgium, with a subsidiary in Bristol, UK.

The company specializes in developing first-in-class antigen-specific immunotherapeutics aimed at treating autoimmune and allergic diseases. Apitope utilizes a proprietary discovery platform to create peptide-based therapies known as "apitopes®," which help restore immune system balance without causing global immune suppression. The company's lead product candidates include ATX-MS-1467 for Multiple Sclerosis and ATX-GD-59 for Graves' Disease, both of which are in clinical development. Apitope also has a robust pipeline targeting conditions such as Uveitis, Factor VIII Inhibitors, Myocarditis, Rheumatoid Arthritis, Type I Diabetes, and common allergies. Additionally, Apitope is working on novel diagnostic products for early detection of autoimmune diseases. The company aims to improve the quality of life for patients suffering from chronic disorders while minimizing the risks associated with traditional immune-suppressing therapies.

## What company datasets say Apitope raised

Funding, as reported

Reported in all **22M** in the source's currency

Rounds **3**

Last round **Series B**

Last round size **13.2M**

Last round date **Sept 2015**

Investors listed **6**

## The company, in detail

What they build

Known for

biotechnology research

Built with from their website

Microsoft Exchange Microsoft 365 Outlook Microsoft 365 Apps & Services Microsoft Email Providers Microsoft Exchange Online

- **Sector:** Research
- **Region:** Vlaams Gewest
- **Revenue:** 10M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/apitope)

## Research in Belgium

Startups like it

- [**Fyteko** Anderlecht · founded 2014 *Raised*](https://millionrounds.com/company/fyteko)
- [**Cellaïon** Mont-Saint-Guibert · founded 2021](https://millionrounds.com/startup/cella-on)
- [**Precirix** Jette · founded 2014](https://millionrounds.com/startup/precirix)
- [**Full-Life Technologies** Gembloux · founded 2021](https://millionrounds.com/startup/full-life-technologies)
- [**Augustine Therapeutics** Leuven · founded 2019](https://millionrounds.com/startup/augustine-therapeutics)
- [**NOVADIP Biosciences S.A.** Mont-Saint-Guibert · founded 2013](https://millionrounds.com/startup/novadip-biosciences-s-a)
- [**EyeD Pharma** Seraing · founded 2012](https://millionrounds.com/startup/eyed-pharma)
- [**atbtherapeutics** Marche-en-Famenne · founded 2018](https://millionrounds.com/startup/atbtherapeutics)

## Is this your company?

Add your raise, your deck and your story, and put Apitope in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)